NCT00900198招募中不适用
Tissue Procurement Protocol for the Developmental Therapeutics Clinic, National Cancer Institute (NCI)
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 5,000
- 试验地点
- 27
- 主要终点
- Collection of research samples
研究概览
简要总结
Background:
-Patients who are being evaluated and/or treated at the NIH Clinical Center and adult patients at participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens.
Objectives:
- To obtain samples from adult and pediatric patients for research purposes from tests and procedures that are done as required by the primary research protocol(s) to which a patient is enrolled or as part of their standard-of-care treatment.
- To obtain samples for research purposes from non-surgical procedures, such as percutaneous biopsies, performed for the sole purpose of obtaining tissue specimens or biological fluids for this protocol.
Eligibility:
-Adult patients (18 years of age and older) and pediatric patients (younger than 18 years of age) who are being evaluated for and/or treated for cancer at the NIH Clinical Center participating sites.
Design:
- This is a multicenter tissue procurement protocol with NCI as the coordinating center.
- For adult patients: specimens for research purposes, as outlined in this protocol, will be obtained from tests and procedures that are done as required by the primary research protocols to which a patient is enrolled or as part of their standard-of-care treatment. Non-surgical procedures, such as percutaneous biopsies, may also be performed for the sole purpose of obtaining tissue specimens or biological fluids for this protocol. Tissues and biological fluids to be procured may include but are not limited to blood, serum, urine, tumor tissue, normal tissue, pleural fluid, CSF, saliva, bronchial alveolar lavage (BAL), circulating tumor cells, hair follicles, and bone marrow. These specimens will be stored with unique identifiers and used to perform only those research studies that are outlined in this protocol.
- For pediatric patients: tumor biopsy/resection tissue used for pediatric preclinical model development will only be from tissue already being obtained as part of a procedure necessary for the patient s clinical care or as part of a primary research protocol; blood specimens will be collected as part of a blood collection already scheduled for the patient s clinical care or as part of the planned pre-procedure bloodwork; volumes collected will not exceed institutional research limits.
- Given the risks associated with any invasive procedure, such as tumor biopsy, the procedure will be discussed in detail with the patients and their parents/guardian (as indicated), including the side effects, prior to obtaining a separate consent for each procedure. A separate consent will not be signed prior to obtaining samples by minimally invasive measures, such as venipuncture.
- This study has two separate consent forms at the NIH Clinical Center: one for adult patients to donate specimens for ongoing research on assay development and studies of molecular pathways, and one for adult and age-appropriate pediatric patients to donate samples for the generation of preclinical models. The study also has consent form templates for adult and pediatric patients at participating sites to donate specimens to create preclinical models.
- Patients may remain on study for the duration of their consent or completion of the planned procedure, whichever comes first.
详细描述
Background:
Patients who are being evaluated and/or treated at the NIH Clinical Center and at participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens.
Objectives:
To obtain specimens from adult and pediatric patients for research purposes from tests and procedures that are done as required by the primary research protocol(s) to which a patient is enrolled or as part of their standard-of-care treatment.
To obtain specimens for research purposes from non-surgical procedures, such as percutaneous biopsies, performed for the sole purpose of obtaining tissue specimens or biological fluids for this protocol.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Other
入排标准
- 年龄范围
- 2 Months 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •INCLUSION CRITERIA - ADULT:
- •Patients 18 years of age and older who are being evaluated and/or treated for cancer at the NIH Clinical Center or at participating sites:
- •Who have a newly diagnosed malignancy for which they have not yet received treatment, or
- •Who have a previously treated malignancy that is now recurrent or currently progressing on treatment indicated by:
- •radiographic evidence of tumor growth and/or new metastases, or
- •CBC w/differential and/or flow cytometry, or
- •documented evidence by the treating physician of signs/symptoms of clinical disease progression, or
- •Who are currently undergoing treatment and for whom disease response has not yet been assessed,
- •--In this circumstance, specimen collection should occur as distant in time from the most recent drug administration as possible such as after completion of a treatment cycle and immediately prior to initiation of the next cycle.
- •Patients with ongoing partial response (PR) or stable disease (SD) are eligible.
- •For solid tumor diagnoses, confirmation of viable malignancy and/or <90% tumor necrosis, fibrosis, or hemorrhage per the final pathology must be reported to the coordinating site for patients enrolled with ongoing PR or SD at the time of specimen collection.
- •For hematologic malignancies, confirmation of viable malignancy must be reported to the coordinating site per the final flow cytometry report.
- •Ability to understand and willingness to sign a written informed consent document indicating their willingness to have their tissue or biologic fluid specimens used for research as outlined in this protocol.
- •At the NIH Clinical Center ONLY:
- •At the PIs discretion, specimens may be collected from patients 18 years of age and older prior to the development of an invasive cancer, who are being evaluated and/or treated for a confirmed familial cancer syndrome such as but not limited to Hereditary Breast and Ovarian Cancer (HBOC), Hereditary Non-polyposis Colorectal Cancer Syndrome or Hereditary Diffuse Gastric Cancer (HDGC) syndrome.
- •Specimens, including blood only, can be collected from patients 18 years of age and older who are being evaluated and/or treated for a hematologic malignancy, including Myelodysplastic Syndrome (MDS) and/or MDS Myeloproliferative Neoplasm (MDS-MPN), that meet all other adult eligibility criteria.
- •Due to the different characteristics of hematologic malignancies versus solid tumor malignancies, including methodology for assessment of disease response, residual disease, and progression, evaluation of these factors for determination of protocol eligibility should be made utilizing established standards such as hematopathology, flow cytometry, immunohistochemical analysis, etc.
排除标准
- •Note: Testing for bloodborne pathogens or other infections is not required for eligibility assessment and will be performed only if clinically indicated. Exclusion criteria for bloodborne pathogens and/or other infections is based on existing documentation in the medical record or patient report of such diagnosis at the time of eligibility assessment, if testing is not obtained for clinical indications.
- •Patients with cancer-like syndromes and/or blood disorders such as but not limited to systemic mastocytosis, Langerhans cell histiocytosis, chronic eosinophilic leukemia/hypereosinophilic syndrome, lymphomatoid granulomatosis, or monoclonal gammopathy of undetermined significance (MGUS).
- •Patients with invasive fungal infections.
- •Patients with active and/or uncontrolled infections or who are still recovering from an infection:
- •All antibiotics, antifungals, or antivirals prescribed for the treatment of an infection should be completed at least 1 week (7 days) prior to collection.
- •No recurrence of fever or other symptoms related to infection for at least 1 week (7 days) following completion of antibiotics.
- •Patients receiving antibiotics, antifungals, or antivirals for prophylaxis are permissible.
- •Antibiotics being administered topically at a location distant from the planned tissue collection site or eye drops for a localized infection are permissible.
- •Note: Use of antibiotics for prophylaxis is not an exclusion.
- •Patients with Human Immunodeficiency Virus (HIV), active or chronic hepatitis (i.e., quantifiable HBV-DNA and/or positive HbsAg, quantifiable HCV-RNA) or known history of HCV or HBV.
- •Patients with Hepatitis A as indicated by anti-HAV IgM reactivity
- •-Note: Patients that are anti-HAV IgG reactive only are not excluded
- •Blood only collections from patients with solid tumors or hematologic malignancy demonstrating partial or stable disease response:
- •Blood will not be collected from patients whose disease demonstrates ongoing partial response or ongoing stable disease given the poor rate of model generation from such specimens.
- •Blood will not be collected from patients between doses within a single treatment cycle.
- •Specimen collections from patients with benign tumors including but not limited to desmoid tumors, carcinoma in situ, or ongoing evidence of complete disease response (CR).
- •INCLUSION CRITERIA - PEDIATRIC:
- •Patients younger than 18 years of age and older than 2 months with a histologically or cytologically confirmed diagnosis of cancer (solid tumor or hematologic malignancy) who are being treated for cancer at the NIH Clinical Center or participating clinical sites and who will already be undergoing a clinically necessary medical procedure during which tumor tissue will be resected or needle biopsy tissue or bone marrow aspirate collected. Tissue from neonates will not be collected.
- •Ability and willingness to assent to participation, utilizing an explanation that is understandable/age appropriate, as well as receiving parental permission.
- •At the NIH Clinical Center ONLY
- •At the PI s discretion, clinically indicated tissue collections may occur from patients with pediatric tumors that are generally benign but are known to undergo malignant transformation, e.g., neurofibromatosis, osteochondromas, pheochromocytoma, etc.
- •EXCLUSION CRITERIA - PEDIATRIC:
- •Note: Testing for bloodborne pathogens or other infections is not required for eligibility assessment and will be performed only if clinically indicated. Exclusion criteria for bloodborne pathogens and/or other infections is based on existing documentation in the medical record or patient report of diagnosis at the time of eligibility assessment, if testing is not obtained for clinical indications.
- •Patients with invasive fungal infections
- •Patients with active and/or uncontrolled infections or who are still recovering from an infection:
- •Actively febrile patients with uncertain etiology of febrile episode
- •All antibiotics should be completed at least 1 week (7 days) prior to collection
- •No recurrence of fever or other symptoms related to infection for at least 1 week (7 days) following completion of antibiotics
- •Note: Use of antibiotics for prophylaxis is not an exclusion.
- •Patients with Human Immunodeficiency Virus (HIV), active or chronic hepatitis (i.e., quantifiable HBV-DNA and/or positive HbsAg, quantifiable HCV-RNA) or known history of HCV or HBV.
- •Patients with Hepatitis A as indicated by anti-HAV IgM reactivity
- •-Note: Patients that are anti-HAV IgG reactive only are not excluded
- •Specimen collections from patients with benign tumors including but not limited to desmoid tumors, carcinoma in situ, or ongoing evidence of complete disease response (CR) based on imaging.
- •Blood only collections from patients with partial or stable disease response:
- •Blood will not be collected from patients whose disease demonstrates ongoing partial response or ongoing stable disease given the poor rate of model generation from such specimens.
- •Blood will not be collected from patients between doses within a single treatment cycle.
研究组 & 干预措施
3/Preclinical Models
Preclinical Models
4/Preclinical Models, Pediatric
Preclinical Models, Pediatric
1/Standard
Standard
干预措施: Biopsy (Procedure)
2/Standard and Preclinical Models
Standard and Preclinical Models
结局指标
主要结局
Collection of research samples
时间窗: Day of collection
Delinking of patient samples for research
次要结局
未报告次要终点
研究者
研究点 (27)
Loading locations...
相似试验
已完成
不适用
Eligibility Screening for a NCI Pediatric Oncology Branch Research StudyOsteosarcomaAcute Lymphoblastic LeukemiaEwing SarcomaNeuroblastomaNeurofibromatosis Type 1NCT00026780National Cancer Institute (NCI)1,720
招募中
不适用
Collection and Storage of Tissue and Blood Samples From Patients With CancerHematopoietic and Lymphatic System NeoplasmMalignant Solid NeoplasmMetastatic Malignant Solid NeoplasmRecurrent Malignant Solid NeoplasmNCT02474160National Cancer Institute LAO5,000
终止
不适用
Tissue Procurement Protocol for Patients Undergoing Treatment for Early-Stage Breast CancerBreast CancerNCT02455882University of Michigan14
已完成
不适用
Tissue Procurement Protocol for Patients Undergoing Neoadjuvant Systemic Therapy for Breast CancerBreast CancerNCT00161265University of Michigan Rogel Cancer Center68
已完成
不适用
Participation in Procurement of Tissue, Serum, Plasma, Cell Bank, DNA and RNA Samples, and Urine for Biological Studies Related to Prostate Cancer and Prostate Cancer Treatment Follow UpProstate CancerNCT01098552Mayo Clinic4,900